There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Sexually transmitted infections (STIs) such as gonorrhea and syphilis have hit record levels in Europe in over a decade, according to new data from the European Centre for Disease Prevention and Control (ECDC).

As per the agency’s latest Annual Epidemiological Reports, there has been a sharp surge in bacterial STIs across Europe. It showed that the notifications of gonorrhea and syphilis, alongside congenital syphilis in 2024, reached their highest levels in over a decade, reflecting sustained transmission across multiple countries.

The ECDC blamed the "widening gaps in testing and prevention” behind the spike in STIs. It also called for urgent targeted action to prevent further spread, including among women of reproductive age.

STI Cases Continue To Climb

The data for 2024 show that:

• gonorrhea cases reached 106,331, representing a 303 per cent increase since 2015.
• syphilis cases more than doubled over the same period to 45,577 cases.
• chlamydia remains the most frequently reported STI with 213,443 cases.
• lymphogranuloma venereum (LGV) also continued to see ongoing transmission, with 3,490 reported cases.

Bruno Ciancio, Head of Unit, Directly Transmitted and Vaccine-Preventable Diseases, said that left untreated, “these infections can cause severe complications, such as chronic pain and infertility and, in the case of syphilis, problems with the heart or nervous system”.

“Most distressingly, between 2023 and 2024, we have seen a near doubling of congenital syphilis, where infections pass directly to newborns, leading to potentially lifelong complications,” Ciancio added.

Disproportionately Affected Groups

Transmission trends vary significantly across different population groups, the ECDC said.

Men who have sex with men remain the most disproportionately affected group, with the steepest long-term increases in gonorrhea and syphilis.

Among heterosexual populations, syphilis is rising, particularly among women of reproductive age, the consequences of which are a near doubling of congenital syphilis cases from 78 in 2023 to 140 in 2024 across 14 countries reporting data.

ECDC Calls For Urgent Action

Reversing increasing trends in STI cases requires accessible prevention services, easier access to testing, faster treatment, and stronger partner notification to stop onward transmission.

The ECDC urged public health authorities to urgently update national STI strategies and strengthen surveillance systems to better monitor the impact of prevention efforts.

“Protecting your sexual health remains straightforward. Use condoms with new or multiple partners, and get tested if you have symptoms, such as pain, discharge, or an ulcer,” Ciancio said.

UK Rolls Out Gonorrhea Vaccine

In the wake of increasing gonorrhea cases, the UK in 2025 rolled out a new vaccine. The vaccine, available at sexual health clinics across England, is being offered to people who are at the highest risk of getting gonorrhea.

This includes gay and bisexual men who have recently had multiple sexual partners and another bacterial STI within the last year. This new program is expected to protect thousands of people and save the NHS over £7.9 million in the next decade.

Gonorrhea Cases Also Rising In The US

Gonorrhea is also increasing in the US, with the 2025 data from the Centers for Disease Control and Prevention showing that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90 per cent since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.

The United States Food and Drug Administration (FDA) in December last year approved two new oral antibiotics to treat gonorrhea: Zoliflodacin and Gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.

Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.

What is Retatrutide?

Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.

Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.

Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently

Retatrutide's results

Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.

What were the side effects of Retatrutide?

On the downside, there were some side effects too. Retatrutide users experienced the following side effects:

1. Diarrhoea
2. Nausea
3. Constipation
4. Urinary tract infections
5. Uncomfortable skin sensations

These have, however, been seen with GLP-1 drugs.

New weight-loss drug coming soon?

Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.

Amid rising cases of the Ebola virus in the Democratic Republic of Congo and Uganda, India and the US have stepped up airport screening.

The latest outbreak, caused by the Bundibugyo Ebola virus, has so far affected nearly 600 people and has caused 139 suspected deaths, as per the latest update by the World Health Organization (WHO). The global health agency has also determined that the deadly outbreak is a “Public Health Emergency of International Concern (PHEIC)”.

India Issues Health Advisory

India today issued a health advisory for passengers arriving from or transiting through Ebola-affected nations. Passengers with symptoms or exposure history should immediately report to the airport health authorities before immigration clearance.

The advisory, issued by the Directorate General of Health Services (DGHS), specifically mentions travelers coming from the Democratic Republic of Congo, Uganda, and South Sudan, all of which have been categorized as "high-risk countries" by the WHO.

The advisory is displayed at the Delhi airport by the Airport Health Organization (APHO). It advises passengers to watch out for symptoms such as:

• fever,
• weakness,
• headache,
• muscle pain,
• vomiting,
• diarrhea,
• sore throat,
• unexplained bleeding.

It also asks travelers who had direct contact with blood or body fluids of a suspected or confirmed Ebola patient to immediately report to the airport health officer or the health desk.

According to the APHO, any traveler developing symptoms within 21 days of arrival should seek immediate medical care and inform authorities about their travel history.

India Reviews Preparedness Measures

On Wednesday, India’s Health Secretary Punya Salila Srivastava chaired a high-level review meeting with health secretaries of all states and Union territories to assess preparedness and response measures for Ebola.

Officials clarified that “no case of Ebola has been detected in India so far”.

However, after the WHO declared Ebola a Public Health Emergency, the Indian government has proactively strengthened surveillance and preparedness measures across the country as an abundant precaution, official sources had said. During the meeting, states and Union territories were advised to ensure readiness at all levels.

The 2026 India-Africa Forum Summit, scheduled for May 28 to 31, was also postponed due to the "evolving health situation in parts of Africa", India's Ministry of External Affairs announced today.

The decision was made in recognition of “the importance of ensuring the full participation and engagement of African leaders and stakeholders, and mindful of the emerging public health situation on the continent", said a joint statement issued by the Indian Ministry of External Affairs and the African Union.

US Tightens Monitoring

Meanwhile, the Centers for Disease Control and Prevention (CDC) has also been enhancing public health screening and traveler monitoring amid a growing Ebola outbreak, and non-US passport holders face entry restrictions if they have been to Uganda, the Democratic Republic of Congo, or South Sudan in the previous 21 days.

“To the American public, the risk to the United States remains low,” said Satish Pillai. “Travelers to the region should avoid contact with sick people, report symptoms immediately, and follow our travel guidance.”

A US missionary doctor infected with the Ebola virus while treating patients in DR Congo has been admitted to Charité hospital in Berlin. The patient was flown to Berlin on a special medical aircraft and then transported to the hospital in a specially designed vehicle escorted by police. The aircraft also carried six other people who had contact with the infected man.

WHO Says Vaccine Could Take Months

Tedros Adhanom Ghebreyesus said he was “deeply concerned about the scale and speed of the epidemic”. He noted that the numbers are expected to rise given the time taken to detect the virus.

The WHO says it could take up to nine months before a vaccine against this particular species of Ebola is ready.

Two possible "candidate vaccines" against the Bundibugyo species are being developed, but neither has gone through clinical trials yet, WHO advisor Dr. Vasee Moorthy said, according to the BBC.

Speaking to journalists in Geneva, Tedros said 51 cases have been confirmed in the Democratic Republic of Congo — where the first case was reported — and two in neighboring Uganda.